Literature DB >> 8247009

Complementation by wild-type p53 of interleukin-6 effects on M1 cells: induction of cell cycle exit and cooperativity with c-myc suppression.

N Levy1, E Yonish-Rouach, M Oren, A Kimchi.   

Abstract

Stable transfection of M1 myeloid leukemia cells with a temperature-sensitive mutant of p53 results in two phenomena that are manifested exclusively at the permissive temperature. On one hand, activation of wild-type p53 by the temperature shift induced an apoptotic type of cell death which could be inhibited by interleukin-6 (IL-6) (E. Yonish-Rouach, D. Resnitzky, J. Lotem, L. Sachs, A. Kimchi, and M. Oren, Nature 352:345-347, 1991). On the other hand, as reported in this work, activated p53 complemented the antiproliferative effects of IL-6 in M1 cells. A shift to the permissive temperature concomitant with or early after IL-6 treatment imposed a novel pattern of cell cycle arrest in which about 95% of the cells were retained within a G0-like quiescent state. This phase was characterized by 2N DNA content and low RNA and protein content. On the molecular level, activation of wild-type p53 transrepressed the c-myc gene but not the cyclin A, D1, or D2 gene, which are all independently suppressed by IL-6 in M1 cells. To further analyze whether c-myc inhibition mediates or complements p53 effects, the p53-transfected M1 cells were infected with a retroviral vector expressing deregulated c-myc, refractory to p53 or IL-6 action. It was found that the process of cell death was not interrupted at all in these M1 c-myc-p53 double transfectants, suggesting that the transrepression of c-myc is not a major obligatory event mediating p53-induced cell death. In addition, some of the antiproliferative effects of activated p53, manifested in the presence of IL-6, could still be transmitted in the background of constitutive c-myc. Yet the context of deregulated c-myc interfered with the final accumulation of cells within a G0-like phase, suggesting complementary interactions between the outcome of p53 activation and of c-myc suppression in the control of cell cycle arrest.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8247009      PMCID: PMC364866          DOI: 10.1128/mcb.13.12.7942-7952.1993

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  44 in total

1.  Induction of apoptosis in fibroblasts by c-myc protein.

Authors:  G I Evan; A H Wyllie; C S Gilbert; T D Littlewood; H Land; M Brooks; C M Waters; L Z Penn; D C Hancock
Journal:  Cell       Date:  1992-04-03       Impact factor: 41.582

2.  Tumor necrosis factor reduces c-myc expression and cooperates with interferon-gamma in HeLa cells.

Authors:  A Yarden; A Kimchi
Journal:  Science       Date:  1986-12-12       Impact factor: 47.728

3.  Growth inhibition by TGF-beta linked to suppression of retinoblastoma protein phosphorylation.

Authors:  M Laiho; J A DeCaprio; J W Ludlow; D M Livingston; J Massagué
Journal:  Cell       Date:  1990-07-13       Impact factor: 41.582

4.  TGF-beta 1 inhibition of c-myc transcription and growth in keratinocytes is abrogated by viral transforming proteins with pRB binding domains.

Authors:  J A Pietenpol; R W Stein; E Moran; P Yaciuk; R Schlegel; R M Lyons; M R Pittelkow; K Münger; P M Howley; H L Moses
Journal:  Cell       Date:  1990-06-01       Impact factor: 41.582

5.  Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line.

Authors:  J P Morgenstern; H Land
Journal:  Nucleic Acids Res       Date:  1990-06-25       Impact factor: 16.971

6.  Various rat adult tissues express only one major mRNA species from the glyceraldehyde-3-phosphate-dehydrogenase multigenic family.

Authors:  P Fort; L Marty; M Piechaczyk; S el Sabrouty; C Dani; P Jeanteur; J M Blanchard
Journal:  Nucleic Acids Res       Date:  1985-03-11       Impact factor: 16.971

7.  Participation of p53 protein in the cellular response to DNA damage.

Authors:  M B Kastan; O Onyekwere; D Sidransky; B Vogelstein; R W Craig
Journal:  Cancer Res       Date:  1991-12-01       Impact factor: 12.701

8.  Interferons and interleukin 6 suppress phosphorylation of the retinoblastoma protein in growth-sensitive hematopoietic cells.

Authors:  D Resnitzky; N Tiefenbrun; H Berissi; A Kimchi
Journal:  Proc Natl Acad Sci U S A       Date:  1992-01-01       Impact factor: 11.205

9.  Factor-binding element in the human c-myc promoter involved in transcriptional regulation by transforming growth factor beta 1 and by the retinoblastoma gene product.

Authors:  J A Pietenpol; K Münger; P M Howley; R W Stein; H L Moses
Journal:  Proc Natl Acad Sci U S A       Date:  1991-11-15       Impact factor: 11.205

10.  Wild-type p53 can down-modulate the activity of various promoters.

Authors:  D Ginsberg; F Mechta; M Yaniv; M Oren
Journal:  Proc Natl Acad Sci U S A       Date:  1991-11-15       Impact factor: 11.205

View more
  36 in total

1.  Alpha interferon suppresses the cyclin D3 and cdc25A genes, leading to a reversible G0-like arrest.

Authors:  N Tiefenbrun; D Melamed; N Levy; D Resnitzky; I Hoffman; S I Reed; A Kimchi
Journal:  Mol Cell Biol       Date:  1996-07       Impact factor: 4.272

2.  Expression of cell cycle-related genes during neuronal apoptosis: is there a distinct pattern?

Authors:  A Shirvan; I Ziv; R Zilkha-Falb; T Machlyn; A Barzilai; E Melamed
Journal:  Neurochem Res       Date:  1998-05       Impact factor: 3.996

3.  p300 binding by E1A cosegregates with p53 induction but is dispensable for apoptosis.

Authors:  S K Chiou; E White
Journal:  J Virol       Date:  1997-05       Impact factor: 5.103

4.  Dual inactivation of RB and p53 pathways in RAS-induced melanomas.

Authors:  N Bardeesy; B C Bastian; A Hezel; D Pinkel; R A DePinho; L Chin
Journal:  Mol Cell Biol       Date:  2001-03       Impact factor: 4.272

5.  Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis.

Authors:  C M Eischen; J D Weber; M F Roussel; C J Sherr; J L Cleveland
Journal:  Genes Dev       Date:  1999-10-15       Impact factor: 11.361

6.  Global Inhibition with Specific Activation: How p53 and MYC Redistribute the Transcriptome in the DNA Double-Strand Break Response.

Authors:  Joshua R Porter; Brian E Fisher; Laura Baranello; Julia C Liu; Diane M Kambach; Zuqin Nie; Woo Seuk Koh; Ji Luo; Jayne M Stommel; David Levens; Eric Batchelor
Journal:  Mol Cell       Date:  2017-08-31       Impact factor: 17.970

7.  Protein mimetic amyloid inhibitor potently abrogates cancer-associated mutant p53 aggregation and restores tumor suppressor function.

Authors:  L Palanikumar; Laura Karpauskaite; Mohamed Al-Sayegh; Ibrahim Chehade; Maheen Alam; Sarah Hassan; Debabrata Maity; Liaqat Ali; Mona Kalmouni; Yamanappa Hunashal; Jemil Ahmed; Tatiana Houhou; Shake Karapetyan; Zackary Falls; Ram Samudrala; Renu Pasricha; Gennaro Esposito; Ahmed J Afzal; Andrew D Hamilton; Sunil Kumar; Mazin Magzoub
Journal:  Nat Commun       Date:  2021-06-25       Impact factor: 14.919

8.  p53-Dependent transcriptional repression of c-myc is required for G1 cell cycle arrest.

Authors:  Jenny S L Ho; Weili Ma; Daniel Y L Mao; Samuel Benchimol
Journal:  Mol Cell Biol       Date:  2005-09       Impact factor: 4.272

9.  MYC prevents apoptosis and enhances endoreduplication induced by paclitaxel.

Authors:  Giuliana Gatti; Giovanna Maresca; Manuela Natoli; Fulvio Florenzano; Angelo Nicolin; Armando Felsani; Igea D'Agnano
Journal:  PLoS One       Date:  2009-05-06       Impact factor: 3.240

Review 10.  Aberrant expression of microRNAs in bladder cancer.

Authors:  Hirofumi Yoshino; Naohiko Seki; Toshihiko Itesako; Takeshi Chiyomaru; Masayuki Nakagawa; Hideki Enokida
Journal:  Nat Rev Urol       Date:  2013-05-28       Impact factor: 14.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.